Oyster Point Pharma, Inc., a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical therapies to treat ocular surface diseases in the United States. It is involved in developing OC-01, a nicotinic acetylcholine receptor agonist that is in Phase IIb clinical trial to treat the signs and symptoms of dry eye disease, as well as Phase III clinical trial for the neurotrophic keratitis. The company was founded in 2018 and is headquartered in Princeton, New Jersey.
Industry, Sector and Symbol
Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
CIKN/A
Phone609-382-9032
Debt
Price-To-Earnings
Sales & Book Value
Annual SalesN/A
Profitability
Miscellaneous
Employees18
Next Earnings DateN/A
OptionableNot Optionable
Oyster Point Pharma (NASDAQ:OYST) Frequently Asked Questions
What is Oyster Point Pharma's stock symbol?
Oyster Point Pharma trades on the NASDAQ under the ticker symbol "OYST."
Has Oyster Point Pharma been receiving favorable news coverage?
Media stories about OYST stock have been trending somewhat negative on Wednesday, InfoTrie reports. InfoTrie identifies negative and positive press coverage by reviewing more than six thousand news and blog sources in real time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Oyster Point Pharma earned a daily sentiment score of -1.6 on InfoTrie's scale. They also assigned media stories about the company a news buzz of 10.0 out of 10, meaning that recent press coverage is extremely likely to have an impact on the company's share price in the immediate future. View News Stories for Oyster Point Pharma.
Who are some of Oyster Point Pharma's key competitors?
Some companies that are related to Oyster Point Pharma include Fate Therapeutics (FATE), Alector (ALEC), Sangamo Therapeutics (SGMO), Orchard Therapeutics (ORTX), Krystal Biotech (KRYS), Aerie Pharmaceuticals (AERI), NanoString Technologies (NSTG), Vericel (VCEL), SpringWorks Therapeutics (SWTX), BAVARIAN NORDIC/S (BVNRY), Twist Bioscience (TWST), Atara Biotherapeutics (ATRA), DBV TECHNOLOGIE/S (DBVT), AVITA MED LTD/S (RCEL) and Osiris Therapeutics (OSIR).
What other stocks do shareholders of Oyster Point Pharma own?
Who are Oyster Point Pharma's key executives?
Oyster Point Pharma's management team includes the folowing people:
- Dr. Jeffrey Nau Ph.D., MMS, Pres, CEO & Director (Age 44)
- Mr. Daniel Lochner, Chief Financial Officer (Age 37)
- Ms. Dawn Pruitt Koffler M.B.A., VP of Marketing
- Mr. John Snisarenko, Chief Commercial Officer (Age 56)
When did Oyster Point Pharma IPO?
(OYST) raised $85 million in an initial public offering on Thursday, October 31st 2019. The company issued 5,000,000 shares at $16.00-$18.00 per share. J.P. Morgan, Cowen and Piper Jaffray acted as the underwriters for the IPO.
When does Oyster Point Pharma's quiet period expire?
Oyster Point Pharma's quiet period expires on Tuesday, December 10th. Oyster Point Pharma had issued 5,000,000 shares in its public offering on October 31st. The total size of the offering was $80,000,000 based on an initial share price of $16.00. During Oyster Point Pharma's quiet period, insiders and underwriters involved in the IPO are restricted from issuing any research reports for the company because of SEC regulations. Following the expiration of the company's quiet period, it's expected that the brokerages that served as underwriters on the stock will initiate research coverage on the company.
How do I buy shares of Oyster Point Pharma?
Shares of OYST can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is Oyster Point Pharma's stock price today?
One share of OYST stock can currently be purchased for approximately $15.20.
How big of a company is Oyster Point Pharma?
What is Oyster Point Pharma's official website?
How can I contact Oyster Point Pharma?
Oyster Point Pharma's mailing address is 202 CARNEGIE CENTER SUITE 109, PRINCETON NJ, 08540. The company can be reached via phone at 609-382-9032 or via email at [email protected]
MarketBeat Community Rating for Oyster Point Pharma (NASDAQ OYST)
MarketBeat's community ratings are surveys of what our community members think about Oyster Point Pharma and other stocks. Vote "Outperform" if you believe OYST will outperform the S&P 500 over the long term. Vote "Underperform" if you believe OYST will underperform the S&P 500 over the long term. You may vote once every thirty days.
